Home / Business and Economy / Novo Nordisk Slashes Wegovy, Ozempic Prices by 50%
Novo Nordisk Slashes Wegovy, Ozempic Prices by 50%
24 Feb
Summary
- Novo Nordisk will reduce prices for Wegovy and Ozempic by up to 50%.
- New lower prices will be effective starting January 2027.
- The company aims to enhance affordability for high-deductible insurance plans.
Novo Nordisk has declared a substantial price reduction for its widely used weight-loss medications, Wegovy and Ozempic. Beginning January 2027, the Danish pharmaceutical giant plans to decrease the monthly cost of these drugs by up to 50%. This strategic move signals intensifying competition among drugmakers vying for dominance in the burgeoning weight-loss drug sector.
Wegovy is slated for a 50% price cut, making its monthly cost $675, while Ozempic will see a 35% reduction. Rybelsus, a diabetes pill also utilized for weight management, will share the same reduced price point. These adjustments position Novo Nordisk to compete more effectively against rivals like Eli Lilly, which offers Mounjaro and Zepbound.
The company framed this decision as a measure to boost affordability, specifically targeting customers enrolled in high-deductible insurance plans. Novo Nordisk emphasized that the price cuts are a response to demands from payers and patients for more accessible pricing. However, the company clarified that these reductions will not affect its direct-to-patient discounted prices.
